Login to Your Account

Other news to note

Tuesday, February 24, 2015

Eagle Pharmaceuticals Inc., of Woodcliff, N.J., reported that the FDA granted seven years of market exclusivity in the U.S. to Ryanodex (dantrolene sodium) for injectable suspension for the treatment of malignant hyperthermia. Ryanodex was designated an orphan drug in August 2013 and was approved by the FDA in July 2014 for this indication.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription